Compare Beyond Meat Inc (BYND) vs Danaher Corporation (DHR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Beyond Meat Inc vs Danaher Corporation — how do they compare? Beyond Meat Inc trades at $0.41 (market cap $215.41M), while Danaher Corporation trades at $205.05 (market cap $145.83B). The key difference: Danaher Corporation is far larger — about 677× Beyond Meat Inc's market cap, and Danaher Corporation pays a 0.77% dividend while Beyond Meat Inc pays none. Which is the better fit depends on your goals.
| BYND | DHR | |
|---|---|---|
Market Cap | $215.41M | $145.83B |
Sector | Consumer Staples | Health |
52-Week High | $3.62 | $242.05 |
52-Week Low | $0.42 | $161.91 |
Enterprise Value | $455.69M | $168.04B |
Dividend Yield | — | 0.77% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Beyond Meat (BYND) trades at $0.52, down 3.29% amid bearish technical signals and recent reverse stock split. The company shows mixed fundamentals with revenue declining from $419M in 2022 to $275M in 2025, though net income turned positive at $178M in 2025 with a 64.6% margin. Technical indicators show bearish momentum with moving averages signaling sell and ADX confirming strong downtrend, while RSI remains neutral. Recent news highlights stock collapse to all-time lows following the 30:1 reverse split announcement in August 2026.
Investment outlook remains highly risky with 57% analyst sell ratings and persistent cash burn from operations. While valuation ratios appear attractive (P/S 0.61, EV/EBITDA 1.28), declining revenue and negative operating cash flow (-$145M in 2025) challenge sustainability. The turnaround strategy focusing on international expansion faces execution risks amid competitive pressures and consumer demand uncertainties.
Danaher (DHR) trades at $209.26, up 2.2% today, with strong technical momentum as the price sits above key support levels. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 EPS expected at $1.92. Fundamentals show robust profitability with a 58.51% gross margin and 15.95% net income margin, though revenue growth has been modest. Analyst sentiment is overwhelmingly positive with 69% buy ratings and a $202.33 consensus price target. Recent news highlights the acquisition of Masimo and new product launches in its biotechnology segment.
The outlook for DHR remains favorable driven by earnings beats and strategic acquisitions, but investors face risks from elevated valuation multiples and potential macroeconomic headwinds. The stock's current technical overbought condition suggests near-term consolidation may occur, yet long-term growth prospects in life sciences support a bullish stance. Key watch points include Q3 2026 earnings results and integration progress of recent acquisitions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Beyond Meat Inc
Beyond Meat is a provider of plant-based meats, such as burgers, sausage, ground beef, and chicken. Unlike other vegetarian products, Beyond Meat seeks to replicate the look, cook, and taste of meat, is targeted to omnivores and vegetarians alike, and is sold in the meat case. The products are widely available across the U.S. and Canada and in 83 additional countries as well. International revenue represented 31% of 2021 sales. The firm's products are available in retail stores and the food-service channel. In 2019, before the pandemic struck, sales were evenly split between these two channels, although mix stood at 70% retail/30% food service in 2021. We think the recovery from the crisis and new deals with McDonald's and Yum Brands will return food-service sales to nearly 50% in time.
Read more on BYND →About Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →
